Published in Ann Rheum Dis on October 02, 2007
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum (2013) 2.17
Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis. Arthritis Res Ther (2015) 1.49
Diagnosis and treatment of cerebral vasculitis. Ther Adv Neurol Disord (2010) 1.47
Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) (2011) 1.16
Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology (2010) 1.10
High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med (2010) 1.04
Vasculitis in systemic sclerosis. Int J Rheumatol (2010) 0.96
An approach to the diagnosis and management of systemic vasculitis. Clin Exp Immunol (2010) 0.95
Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther (2012) 0.93
Cardiac involvement in Wegener's granulomatosis resistant to induction therapy. Eur Radiol (2011) 0.92
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Ann Rheum Dis (2010) 0.87
Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis. J Am Soc Nephrol (2015) 0.87
Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol (2012) 0.86
Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int (2011) 0.85
The immunopathology of ANCA-associated vasculitis. Semin Immunopathol (2014) 0.83
Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol (2015) 0.83
Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis). Ther Clin Risk Manag (2014) 0.82
ANCA-associated vasculitides-lessons from the adult literature. Pediatr Nephrol (2010) 0.82
Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis. Semin Arthritis Rheum (2014) 0.78
Immune mediated diseases and immune modulation in the neurocritical care unit. Neurotherapeutics (2012) 0.78
Variability of the impact of adverse events on physicians' decision making. BMC Med Inform Decis Mak (2014) 0.78
Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients. Rheumatol Int (2016) 0.78
Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin Rheumatol (2016) 0.77
Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol (2013) 0.77
Pulmonary arterial hypertension associated with rare cause of ANCA-associated vasculitis misdiagnosed as idiopathic one. Int J Clin Exp Med (2015) 0.77
Biomarkers Predict Relapse in Granulomatosis with Polyangiitis. J Biomark (2014) 0.76
Hypersensitivity pneumonitis associated with azathioprine therapy in a patient with granulomatosis with polyangiitis. Rheumatol Int (2016) 0.76
ANCA-associated vasculitis: from bench research to novel treatments. Nat Rev Nephrol (2009) 0.76
A 46-year-old man with Fever and numbness of limbs. Tanaffos (2011) 0.75
Make the grade for Wegener's granulomatosis after kidney transplantation. NDT Plus (2009) 0.75
Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives. Ther Clin Risk Manag (2015) 0.75
Improved survival in granulomatosis with polyangiitis: A general population-based study. Semin Arthritis Rheum (2015) 0.75
Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease. Arthritis Rheumatol (2016) 0.75
Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service. BMC Musculoskelet Disord (2015) 0.75
Association of the Charlson comorbidity index with renal outcome and all-cause mortality in antineutrophil cytoplasmatic antibody-associated vasculitis. Medicine (Baltimore) (2014) 0.75
Successful induction of granulomatosis with polyangiitis with tacrolimus. Indian J Nephrol (2015) 0.75
CD4(+)CD28(null) T Cells are related to previous cytomegalovirus infection but not to accelerated atherosclerosis in ANCA-associated vasculitis. Rheumatol Int (2017) 0.75
Long-term outcomes in antineutrophil cytoplasmic autoantibody-positive eosinophilic granulomatosis with polyangiitis patients with renal involvement: a retrospective study of 14 Chinese patients. BMC Nephrol (2016) 0.75
Urinary immunoglobulin G to albumin ratio and N-Acetyl-Beta-D-Glucosaminidase as early predictors of therapeutic response in ANCA-associated glomerulonephritis. PLoS One (2013) 0.75
The downsides of a major medical advance. Arthritis Care Res (Hoboken) (2010) 0.75
Leukocytoclastic vasculitis: a window to systemic churg strauss syndrome. Indian J Dermatol (2012) 0.75
Androgen deficiency in male patients diagnosed with ANCA-associated vasculitis: a cause of fatigue and reduced health-related quality of life? Arthritis Res Ther (2013) 0.75
Coming of Age--CC Chemokine Ligand 18 in ANCA-Associated Vasculitis. J Am Soc Nephrol (2015) 0.75
An increase of CD83+ dendritic cells ex vivo correlates with increased regulatory T cells in patients with active eosinophilic granulomatosis and polyangiitis. BMC Immunol (2014) 0.75
Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis. Clin Rev Allergy Immunol (2017) 0.75
Birmingham vasculitis activity score at diagnosis is a significant predictor of relapse of polyarteritis nodosa. Rheumatol Int (2017) 0.75
Clinical, serological and histological determinants of patient and renal outcome in ANCA-associated vasculitis with renal involvement: an analysis from a referral centre. Int Urol Nephrol (2017) 0.75
[Prognosis and therapy of inflammatory rheumatic diseases : Impact of renal manifestations]. Z Rheumatol (2015) 0.75
Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int (2017) 0.75
Strength-duration curves for repetitive stimulation of medullated nerve. J Physiol (1934) 15.94
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature (2001) 10.96
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88
Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med (1980) 5.80
EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis (2008) 4.88
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
A dust-obscured massive maximum-starburst galaxy at a redshift of 6.34. Nature (2013) 4.43
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) (2002) 3.87
Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum (2001) 3.67
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
EULAR recommendations for the management of Behçet disease. Ann Rheum Dis (2008) 3.37
Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med (1990) 3.37
Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med (1989) 3.33
International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) Am J Clin Pathol (1999) 3.31
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum (2001) 3.15
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum (2000) 3.06
Heatstroke in well-wrapped infants. Lancet (1979) 2.81
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
[Hannover Functional Questionnaire in ambulatory diagnosis of functional disability caused by backache]. Rehabilitation (Stuttg) (1996) 2.79
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1998) 2.78
Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) (1996) 2.72
Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol (2001) 2.69
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J (2010) 2.56
Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS Study Group. European Prospective Osteoporosis Study Group. Osteoporos Int (2000) 2.52
Arrangement of late RNAs transcribed from a 7.1-kilobase EcoRI vaccinia virus DNA fragment. J Virol (1984) 2.48
Group A beta-hemolytic streptococci resistant to erythromycin and lincomycin. N Engl J Med (1968) 2.44
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood (1989) 2.37
Stapled haemorrhoidopexy for the treatment of haemorrhoids: a systematic review. Colorectal Dis (2008) 2.35
Bilateral human fetal striatal transplantation in Huntington's disease. Neurology (2002) 2.34
Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum (1997) 2.31
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis (2008) 2.25
The combined use of HLA-B5 and the pathergy test as diagnostic markers of Behçet's disease in Turkey. J Rheumatol (1980) 2.20
Methane-oxidizing microorganisms. Microbiol Rev (1981) 2.17
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med (1996) 2.17
Anticytoplasmic antibodies in Wegener's granulomatosis. Lancet (1986) 2.12
Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis (2008) 2.12
Elements of fibromyalgia in an open population. Rheumatology (Oxford) (2003) 2.11
How should different life expectancies be valued? BMJ (1998) 2.10
Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol (1987) 2.09
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) (2007) 2.02
Improved differentiation between Churg-Strauss syndrome and Wegener's granulomatosis by an artificial neural network. Arthritis Rheum (2001) 2.00
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) (2002) 1.98
Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) (2002) 1.96
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) (2007) 1.95
Endomysial antibody: is it the best screening test for coeliac disease? Gut (1992) 1.93
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum (2008) 1.90
Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum (2000) 1.89
Antibiotic treatment of Yersinia enterocolitica septicemia: a retrospective review of 43 cases. Clin Infect Dis (1993) 1.88
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol (1989) 1.87
The arthritis of Behçet's disease: a prospective study. Ann Rheum Dis (1983) 1.86
Knee replacement surgery for osteoarthritis: effectiveness, practice variations, indications and possible determinants of utilization. Rheumatology (Oxford) (1999) 1.84
Isolation and characterisation of a bipotential haematopoietic cell line. Nature (1979) 1.80
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab (1996) 1.80
Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int (2002) 1.78
Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol (1994) 1.76
Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (1998) 1.76
Haemophilus endocarditis: report of 42 cases in adults and review. Haemophilus Endocarditis Study Group. Clin Infect Dis (1997) 1.75
Early Permian bipedal reptile. Science (2000) 1.73
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) (2003) 1.71
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
The high prevalence of HLA-B5 in Behçet's disease. Clin Exp Immunol (1977) 1.69
STARR with Contour Transtar: prospective multicentre European study. Colorectal Dis (2008) 1.69
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Two functional states of the CD11b A-domain: correlations with key features of two Mn2+-complexed crystal structures. J Cell Biol (1998) 1.67
B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol (2009) 1.67
Primary osteoarthrosis of the knee or hip. Prevalence of Heberden nodes in relation to age and sex. JAMA (1975) 1.67
Cell death, chromosome damage and mitotic delay in normal human, ataxia telangiectasia and retinoblastoma fibroblasts after x-irradiation. Int J Radiat Biol Relat Stud Phys Chem Med (1981) 1.66
The OVIS study: health related quality of life measured by the EORTC QLQ-C30 and -BR23 in German female patients with breast cancer from Schleswig-Holstein. Qual Life Res (2007) 1.64